All In Biotech

Drug Trial Radar · NCT04604652

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 27, 2021

Primary completion

May 31, 2022

Study completion May 31, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.

Conditions

  • Primary Biliary Cholangitis
  • Primary Biliary Cirrhosis
  • Cholangitis
  • Cholestasis
  • Biliary Tract Diseases
  • Bile Duct Stricture

Interventions

  • HTD1801 (BUDCA)Drug

    HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to BaselineTime frame: Baseline to Week 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Schiff Center for Liver Disease

    Miami, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health Services

    Detroit, Michigan

  • St. Louis University

    St Louis, Missouri

  • Northshore University Hospital

    Manhasset, New York

  • University GI

    Providence, Rhode Island

  • Baylor Research Institute

    Dallas, Texas

  • The Texas Liver Institute

    San Antonio, Texas

  • Liver Institute of Virginia

    Newport News, Virginia

  • Bon Secours Liver Institute of Richmond

    Richmond, Virginia

  • Liver Institute Northwest

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.